{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:33:22Z","timestamp":1783017202260,"version":"3.54.6"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Risk stratification in non-ischemic cardiomyopathies (NICM) remains challenging despite guideline-based phenotypic classification using multimodal diagnostics including endomyocardial biopsy (EMB). We aimed to identify EMB-derived histological and molecular markers that improve phenotypic characterization and long-term risk stratification in patients with NICM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cohort study, 703 consecutive patients with symptomatic NICM underwent standardized multimodal evaluation, including clinical assessment, cardiac imaging, and endomyocardial biopsy. Biopsy specimens were analyzed using histology, immunohistochemistry, and targeted myocardial mRNA profiling. Associations between endomyocardial markers, and fibroinflammatory remodeling, imaging parameters, and molecular signatures were assessed cross-sectionally. Long-term prognostic relevance was evaluated using survival and multivariable prediction analyses during follow-up of up to fifteen years for all-cause mortality, cardiovascular mortality, implantable cardioverter-defibrillator (ICD) implantation, and appropriate ICD discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated myocardial Gremlin-1 expression was associated with increased fibrosis, adverse cardiac remodelling, reduced left ventricular function, and enrichment of pro-fibrotic and inflammatory mRNA signalling pathways. Myocardial and circulating Gremlin-1 expression was independently associated with all-cause and cardiovascular mortality, and ICD implantation and discharge. Machine learning\u2013based phenotyping using histological EMB data identified Gremlin-1 as a key predictive feature of poor prognosis. Incorporation of Gremlin-1 into predictive models significantly improved long-term cardiovascular risk stratification in NICM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our results unveil that Gremlin-1 is associated with inflammation and cardiac remodelling in patients with NICM, and patients with Gremlin-1\n                      <jats:sup>+<\/jats:sup>\n                      EMB and high plasmatic Gremlin-1 concentrations are at elevated risk to develop adverse cardiovascular events. Thus, the histological evaluation of Gremlin-1 may help to improve risk discrimination and management of NICM and HF patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01762-9","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:42:12Z","timestamp":1783006932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endomyocardial Gremlin-1 is associated with structural remodeling and adverse clinical outcomes in non-ischemic cardiomyopathy"],"prefix":"10.1038","volume":"6","author":[{"given":"Tobias","family":"Harm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-2498","authenticated-orcid":false,"given":"Karin","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-8439","authenticated-orcid":false,"given":"Patrick","family":"Krumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Heinzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Dingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Toskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Seizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-4085","authenticated-orcid":false,"given":"Oliver","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Schreieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1124-9592","authenticated-orcid":false,"given":"Meinrad Paul","family":"Gawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Anne Lydia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107, P. M. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail 21, 553\u2013576 (2019).","journal-title":"Eur. J. Heart Fail"},{"key":"1762_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","volume":"121","author":"WJ McKenna","year":"2017","unstructured":"McKenna, W. J., Maron, B. J. & Thiene, G. Classification, epidemiology, and global burden of cardiomyopathies. Circ. Res. 121, 722\u2013730 (2017).","journal-title":"Circ. Res."},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur. Heart J. 44, 3503\u20133626 (2023).","journal-title":"Eur. Heart J."},{"key":"1762_CR4","first-page":"e533","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142, e533\u2013e557 (2020).","journal-title":"Circulation"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/CIRCRESAHA.117.311812","volume":"121","author":"E Braunwald","year":"2017","unstructured":"Braunwald, E. Cardiomyopathies. Circ. Res. 121, 711\u2013721 (2017).","journal-title":"Circ. Res."},{"key":"1762_CR6","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2006.07.049","volume":"48","author":"RG Assomull","year":"2006","unstructured":"Assomull, R. G. et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1977\u20131985 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1762_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe, C. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 18, 169\u2013193 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1762_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/clc.22509","volume":"39","author":"KA M\u00fcller","year":"2016","unstructured":"M\u00fcller, K. A. et al. High plasma levels of Gremlin-1 and macrophage migration inhibitory factor, but not their ratio, indicate an increased risk for acute coronary syndrome in patients with type 2 Diabetes Mellitus. Clin. Cardiol. 39, 201\u2013206 (2016).","journal-title":"Clin. Cardiol."},{"key":"1762_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ehf2.12298","volume":"5","author":"KAL Mueller","year":"2018","unstructured":"Mueller, K. A. L. et al. Myocardial expression of the anaphylatoxin receptor C3aR is associated with cardiac inflammation and prognosis in patients with non-ischaemic heart failure. ESC Heart Fail. 5, 846\u2013857 (2018).","journal-title":"ESC Heart Fail."},{"key":"1762_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00392-015-0871-y","volume":"104","author":"CS Zuern","year":"2015","unstructured":"Zuern, C. S. et al. Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. Clin. Res Cardiol. 104, 1033\u20131043 (2015).","journal-title":"Clin. Res Cardiol."},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 17, 269\u2013285 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy, S. P., Kakkar, R., McCarthy, C. P. & Januzzi, J. L. Inflammation in Heart Failure. J. Am. Coll. Cardiol. 75, 1324\u20131340 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1762_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn, V. S. et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 8, 712\u2013724 (2020).","journal-title":"JACC Heart Fail."},{"key":"1762_CR14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1762_CR15","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373\u2013498 (2021).","journal-title":"Eur. Heart J."},{"key":"1762_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott, P. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 29, 270\u2013276 (2008).","journal-title":"Eur. Heart J."},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/01.CIR.0000118493.13323.81","volume":"109","author":"H Mahrholdt","year":"2004","unstructured":"Mahrholdt, H. et al. Cardiovascular Magnetic Resonance Assessment of Human Myocarditis. Circulation 109, 1250\u20131258 (2004).","journal-title":"Circulation"},{"key":"1762_CR19","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"1762_CR20","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur. Heart J. 44, 4043\u20134140 (2023).","journal-title":"Eur. Heart J."},{"key":"1762_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41, 111\u2013188 (2019).","journal-title":"Eur. Heart J."},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","volume":"280","author":"S Kasahara","year":"2019","unstructured":"Kasahara, S. et al. Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. Int. J. Cardiol. 280, 184\u2013189 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1762_CR23","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"1762_CR24","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld, K. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 43, 3997\u20134126 (2022).","journal-title":"Eur. Heart J."},{"key":"1762_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cardfail.2018.03.004","volume":"24","author":"RE Hershberger","year":"2018","unstructured":"Hershberger, R. E. et al. Genetic evaluation of Cardiomyopathy-A Heart Failure Society of America practice guideline. J. Card. Fail 24, 281\u2013302 (2018).","journal-title":"J. Card. Fail"},{"key":"1762_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron, B. J. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113, 1807\u20131816 (2006).","journal-title":"Circulation"},{"key":"1762_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ehjci\/jeac051","volume":"23","author":"N Menghoum","year":"2022","unstructured":"Menghoum, N., Vos, J. L., Pouleur, A.-C., Nijveldt, R. & Gerber, B. L. How to evaluate cardiomyopathies by cardiovascular magnetic resonance parametric mapping and late gadolinium enhancement. Eur. Heart J. - Cardiovasc. Imaging 23, 587\u2013589 (2022).","journal-title":"Eur. Heart J. - Cardiovasc. Imaging"},{"key":"1762_CR28","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2021.03.008","volume":"77","author":"H Cui","year":"2021","unstructured":"Cui, H. et al. Myocardial histopathology in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 77, 2159\u20132170 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1762_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.108.840827","volume":"121","author":"FI Marcus","year":"2010","unstructured":"Marcus, F. I. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia. Circulation 121, 1533\u20131541 (2010).","journal-title":"Circulation"},{"key":"1762_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijcard.2020.06.005","volume":"319","author":"D Corrado","year":"2020","unstructured":"Corrado, D. et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int. J. Cardiol. 319, 106\u2013114 (2020).","journal-title":"Int. J. Cardiol."},{"key":"1762_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/cvr\/cvx150","volume":"113","author":"ET Hoorntje","year":"2017","unstructured":"Hoorntje, E. T. et al. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovasc. Res. 113, 1521\u20131531 (2017).","journal-title":"Cardiovasc. Res."},{"key":"1762_CR32","doi-asserted-by":"crossref","unstructured":"Brodehl, A. & Gerull, B. Genetic Insights into Primary Restrictive Cardiomyopathy. J. Clin. Med. 11, (2022).","DOI":"10.20944\/preprints202203.0265.v1"},{"key":"1762_CR33","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia, P. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 42, 1554\u20131568 (2021).","journal-title":"Eur. Heart J."},{"key":"1762_CR34","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","volume":"43","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi, C. et al. Restrictive cardiomyopathy: definition and diagnosis. Eur. Heart J. 43, 4679\u20134693 (2022).","journal-title":"Eur. Heart J."},{"key":"1762_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11886-022-01680-x","volume":"24","author":"E Ammirati","year":"2022","unstructured":"Ammirati, E. et al. State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Curr. Cardiol. Rep. 24, 597\u2013609 (2022).","journal-title":"Curr. Cardiol. Rep."},{"key":"1762_CR36","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2017.02.049","volume":"69","author":"KAL Mueller","year":"2017","unstructured":"Mueller, K. A. L. et al. Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy. J. Am. Coll. Cardiol. 69, 2160\u20132172 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1762_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurjhf\/hfs185","volume":"15","author":"CS Zuern","year":"2013","unstructured":"Zuern, C. S. et al. Cyclophilin A predicts clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy. Eur. J. Heart Fail 15, 176\u2013184 (2013).","journal-title":"Eur. J. Heart Fail"},{"key":"1762_CR38","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijcard.2015.11.014","volume":"203","author":"KA Mueller","year":"2016","unstructured":"Mueller, K. A. et al. Prognostic impact of macrophage migration inhibitory factor in patients with non-ischemic heart failure undergoing endomyocardial biopsy. Int J. Cardiol. 203, 656\u2013659 (2016).","journal-title":"Int J. Cardiol."},{"key":"1762_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cardfail.2021.04.010","volume":"27","author":"PM Seferovi\u0107","year":"2021","unstructured":"Seferovi\u0107, P. M. et al. Heart Failure Association, Heart Failure Society of America, and Japanese Heart failure society position statement on endomyocardial biopsy. J. Card. Fail 27, 727\u2013743 (2021).","journal-title":"J. Card. Fail"},{"key":"1762_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.carpath.2011.10.001","volume":"21","author":"O Leone","year":"2012","unstructured":"Leone, O. et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 21, 245\u2013274 (2012).","journal-title":"Cardiovasc Pathol."},{"key":"1762_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10741-012-9355-6","volume":"18","author":"C Basso","year":"2013","unstructured":"Basso, C., Calabrese, F., Angelini, A., Carturan, E. & Thiene, G. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail Rev. 18, 673\u2013681 (2013).","journal-title":"Heart Fail Rev."},{"key":"1762_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.108.769489","volume":"118","author":"I Kindermann","year":"2008","unstructured":"Kindermann, I. et al. Predictors of outcome in patients with suspected myocarditis. Circulation 118, 639\u2013648 (2008).","journal-title":"Circulation"},{"key":"1762_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.thromres.2023.08.004","volume":"230","author":"T Harm","year":"2023","unstructured":"Harm, T. et al. Thrombus architecture is influenced by the antiplatelet loading treatment in patients with acute myocardial infarction. Thrombosis Res. 230, 45\u201354 (2023).","journal-title":"Thrombosis Res."},{"key":"1762_CR44","doi-asserted-by":"crossref","unstructured":"Ulgen, E., Ozisik, O. & Sezerman, O.U. pathfindR: An R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front. Genet. 10, 858 (2019).","DOI":"10.3389\/fgene.2019.00858"},{"key":"1762_CR45","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","volume":"30","author":"Z Gu","year":"2014","unstructured":"Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811\u20132812 (2014).","journal-title":"Bioinformatics"},{"key":"1762_CR46","doi-asserted-by":"crossref","unstructured":"Harm, T. et al. Large-scale lipidomics profiling reveals characteristic lipid signatures associated with an increased cardiovascular risk. Clin. Res. Cardiol. (2023).","DOI":"10.1093\/eurheartj\/ehad655.1370"},{"key":"1762_CR47","first-page":"3","volume":"1","author":"H Aretz","year":"1986","unstructured":"Aretz, H. Myocarditis: a histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1, 3\u201314 (1986).","journal-title":"Am. J. Cardiovasc. Pathol."},{"key":"1762_CR48","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio, A. L. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636\u20132648 (2013).","journal-title":"Eur. Heart J."},{"key":"1762_CR49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","volume":"34","author":"AP Ambrosy","year":"2013","unstructured":"Ambrosy, A. P. et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur. Heart J. 34, 835\u2013843 (2013).","journal-title":"Eur. Heart J."},{"key":"1762_CR50","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O\u2019Mahony","year":"2014","unstructured":"O\u2019Mahony, C. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur. Heart J. 35, 2010\u20132020 (2014).","journal-title":"Eur. Heart J."},{"key":"1762_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jacc.2024.06.046","volume":"84","author":"DJ Hammersley","year":"2024","unstructured":"Hammersley, D. J. et al. Arrhythmic risk stratification by cardiovascular magnetic resonance imaging in patients with nonischemic cardiomyopathy. JACC 84, 1407\u20131420 (2024).","journal-title":"JACC"},{"key":"1762_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0008-6363(03)00437-1","volume":"60","author":"JW Mason","year":"2003","unstructured":"Mason, J. W. Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovasc. Res. 60, 5\u201310 (2003).","journal-title":"Cardiovasc. Res."},{"key":"1762_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26115-y","volume":"8","author":"M-N Nguyen","year":"2018","unstructured":"Nguyen, M.-N. et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci. Rep. 8, 8213 (2018).","journal-title":"Sci. Rep."},{"key":"1762_CR54","volume":"11","author":"A Bay\u00e9s-Genis","year":"2018","unstructured":"Bay\u00e9s-Genis, A., Gonz\u00e1lez, A. & Lup\u00f3n, J. ST2 in Heart Failure. Circulation: Heart Fail. 11, e005582 (2018).","journal-title":"Circulation: Heart Fail."},{"key":"1762_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/CIRCHEARTFAILURE.111.962027","volume":"4","author":"E Barasch","year":"2011","unstructured":"Barasch, E. et al. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ. Heart Fail 4, 733\u2013739 (2011).","journal-title":"Circ. Heart Fail"},{"key":"1762_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41590-021-00920-6","volume":"22","author":"VN Kapoor","year":"2021","unstructured":"Kapoor, V. N. et al. Gremlin 1(+) fibroblastic niche maintains dendritic cell homeostasis in lymphoid tissues. Nat. Immunol. 22, 571\u2013585 (2021).","journal-title":"Nat. Immunol."},{"key":"1762_CR57","doi-asserted-by":"publisher","first-page":"14842","DOI":"10.1073\/pnas.0606857103","volume":"103","author":"JB Sneddon","year":"2006","unstructured":"Sneddon, J. B. et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. USA 103, 14842\u201314847 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1762_CR58","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2014.09.010","volume":"237","author":"II M\u00fcller","year":"2014","unstructured":"M\u00fcller, I. I. et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis 237, 426\u2013432 (2014).","journal-title":"Atherosclerosis"},{"key":"1762_CR59","doi-asserted-by":"publisher","first-page":"31635","DOI":"10.1074\/jbc.M113.477745","volume":"288","author":"I M\u00fcller","year":"2013","unstructured":"M\u00fcller, I. et al. Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE-\/- Mice. J. Biol. Chem. 288, 31635\u201331645 (2013).","journal-title":"J. Biol. Chem."},{"key":"1762_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s44161-024-00432-0","volume":"3","author":"C Perez-Shibayama","year":"2024","unstructured":"Perez-Shibayama, C. et al. Bone morphogenic protein-4 availability in the cardiac microenvironment controls inflammation and fibrosis in autoimmune myocarditis. Nat. Cardiovasc. Res. 3, 301\u2013316 (2024).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1762_CR61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.CIR.0000155616.07901.35","volume":"111","author":"U K\u00fchl","year":"2005","unstructured":"K\u00fchl, U. et al. High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With \u201cIdiopathic\u201d Left Ventricular Dysfunction. Circulation 111, 887\u2013893 (2005).","journal-title":"Circulation"},{"key":"1762_CR62","doi-asserted-by":"crossref","unstructured":"Harm, T., Keren, A. & Borst, O. Parvovirus B19 - more than a bystander in the prognosis of non-ischaemic heart failure. Eur. J. Heart Fail. 27, 3069\u20133071 (2025).","DOI":"10.1002\/ejhf.70008"},{"key":"1762_CR63","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/CIRCULATIONAHA.120.048477","volume":"143","author":"I Klem","year":"2021","unstructured":"Klem, I. et al. Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy. Circulation 143, 1343\u20131358 (2021).","journal-title":"Circulation"},{"key":"1762_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015351","volume":"9","author":"S Greulich","year":"2020","unstructured":"Greulich, S. et al. Predictors of Mortality in Patients With Biopsy-Proven Viral Myocarditis: 10-Year Outcome Data. J. Am. Heart Assoc. 9, e015351 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1762_CR65","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/ehjci\/jeaa423","volume":"22","author":"S Greulich","year":"2021","unstructured":"Greulich, S. et al. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study. Eur. Heart J. - Cardiovasc. Imaging 22, 732\u2013741 (2021).","journal-title":"Eur. Heart J. - Cardiovasc. Imaging"},{"key":"1762_CR66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ehjci\/jeu182","volume":"16","author":"LM Iles","year":"2015","unstructured":"Iles, L. M. et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur. Heart J. Cardiovasc. Imaging 16, 14\u201322 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"1762_CR67","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1093\/eurheartj\/ehaa159","volume":"41","author":"J Corral-Acero","year":"2020","unstructured":"Corral-Acero, J. et al. The \u2018Digital Twin\u2019 to enable the vision of precision cardiology. Eur. Heart J. 41, 4556\u20134564 (2020).","journal-title":"Eur. Heart J."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01762-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:33:57Z","timestamp":1783013637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01762-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01762-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}